135 related articles for article (PubMed ID: 22633189)
1. Vitamin D receptor activation and prevention of arterial ageing.
Cozzolino M; Stucchi A; Rizzo MA; Soldati L; Cusi D; Ciceri P; Brenna I; Elli F; Gallieni M
Nutr Metab Cardiovasc Dis; 2012 Jul; 22(7):547-52. PubMed ID: 22633189
[TBL] [Abstract][Full Text] [Related]
2. Reprint of: Vitamin D receptor activation and prevention of arterial ageing.
Cozzolino M; Stucchi A; Rizzo MA; Soldati L; Cusi D; Ciceri P; Brenna I; Elli F; Gallieni M
Nutr Metab Cardiovasc Dis; 2013 Dec; 23 Suppl 1():S31-6. PubMed ID: 23199645
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular disease in chronic kidney failure: the role of VDR activators.
Wu-Wong JR; Tian J; Nakane M; Ma J; Fey TA; Kroeger P; Fryer RM; Reinhart GA
Curr Opin Investig Drugs; 2006 Mar; 7(3):206-13. PubMed ID: 16555680
[TBL] [Abstract][Full Text] [Related]
4. Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism.
Cozzolino M; Brancaccio D
Expert Opin Pharmacother; 2008 Apr; 9(6):947-54. PubMed ID: 18377338
[TBL] [Abstract][Full Text] [Related]
5. Vascular calcification in chronic kidney failure: role of vitamin D receptor.
Wu-Wong JR; Melnick J
Curr Opin Investig Drugs; 2007 Mar; 8(3):237-47. PubMed ID: 17408120
[TBL] [Abstract][Full Text] [Related]
6. The impact of paricalcitol on left ventricular hypertrophy.
Cozzolino M; Ronco C
Contrib Nephrol; 2011; 171():161-165. PubMed ID: 21625106
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular disease in chronic kidney failure: is there a role for vitamin D analogs?
Wu-Wong JR; Nakane M; Traylor L; Ruan X; Kroeger PE; Tian J
Curr Opin Investig Drugs; 2005 Mar; 6(3):245-54. PubMed ID: 15816500
[TBL] [Abstract][Full Text] [Related]
8. Effects of vitamin D analogs on the expression of plasminogen activator inhibitor-1 in human vascular cells.
Wu-Wong JR; Nakane M; Ma J
Thromb Res; 2006; 118(6):709-14. PubMed ID: 16371233
[TBL] [Abstract][Full Text] [Related]
9. [Vitamin D metabolism and current options for therapeutic activation of vitamin D receptor in patients with chronic kidney disease or renal failure].
Dusilová Sulková S
Vnitr Lek; 2012 Nov; 58(11):839-49. PubMed ID: 23256830
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of vitamin D receptor activators on vascular calcification in uremic rats.
Mizobuchi M; Finch JL; Martin DR; Slatopolsky E
Kidney Int; 2007 Sep; 72(6):709-15. PubMed ID: 17597697
[TBL] [Abstract][Full Text] [Related]
11. Vitamin D receptor activation and cardiovascular disease.
Gonzalez-Parra E; Rojas-Rivera J; Tuñón J; Praga M; Ortiz A; Egido J
Nephrol Dial Transplant; 2012 Dec; 27 Suppl 4():iv17-21. PubMed ID: 23258805
[TBL] [Abstract][Full Text] [Related]
12. Vitamin D receptor agonists increase klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet.
Lau WL; Leaf EM; Hu MC; Takeno MM; Kuro-o M; Moe OW; Giachelli CM
Kidney Int; 2012 Dec; 82(12):1261-70. PubMed ID: 22932118
[TBL] [Abstract][Full Text] [Related]
13. Impaired arterial vitamin D signaling occurs in the development of vascular calcification.
Lim K; Molostvov G; Lubczanska M; Fletcher S; Bland R; Hiemstra TF; Zehnder D
PLoS One; 2020; 15(11):e0241976. PubMed ID: 33211721
[TBL] [Abstract][Full Text] [Related]
14. Vitamin D treatment in chronic kidney disease.
Andress DL
Semin Dial; 2005; 18(4):315-21. PubMed ID: 16076355
[TBL] [Abstract][Full Text] [Related]
15. Differential effects of vitamin D analogs on vascular calcification.
Cardús A; Panizo S; Parisi E; Fernandez E; Valdivielso JM
J Bone Miner Res; 2007 Jun; 22(6):860-6. PubMed ID: 17352647
[TBL] [Abstract][Full Text] [Related]
16. Role of vitamin D in cardiovascular disease.
Verhave G; Siegert CE
Neth J Med; 2010 Mar; 68(3):113-8. PubMed ID: 20308705
[TBL] [Abstract][Full Text] [Related]
17. Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy.
Sanchez-Niño MD; Bozic M; Córdoba-Lanús E; Valcheva P; Gracia O; Ibarz M; Fernandez E; Navarro-Gonzalez JF; Ortiz A; Valdivielso JM
Am J Physiol Renal Physiol; 2012 Mar; 302(6):F647-57. PubMed ID: 22169009
[TBL] [Abstract][Full Text] [Related]
18. Endothelial dysfunction and chronic kidney disease: treatment options.
Wu-Wong JR
Curr Opin Investig Drugs; 2008 Sep; 9(9):970-82. PubMed ID: 18729004
[TBL] [Abstract][Full Text] [Related]
19. Vitamin D receptor ligand therapy in chronic kidney disease.
Gonzalez E
Clin Nephrol; 2008 Oct; 70(4):271-83. PubMed ID: 18826852
[TBL] [Abstract][Full Text] [Related]
20. VDRA therapy is associated with improved survival in dialysis patients with serum intact PTH ≤ 150 pg/mL: results of the Italian FARO Survey.
Cozzolino M; Brancaccio D; Cannella G; Messa P; Gesualdo L; Marangella M; LoDeserto C; Pozzato M; Rombolà G; Costanzo AM; di Luzio Paparatti U; Mazzaferro S;
Nephrol Dial Transplant; 2012 Sep; 27(9):3588-94. PubMed ID: 22523119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]